HD-OPM Archive

Lp(a): the inherited risk factor everyone should test once

What lipoprotein(a) is, why it raises the risk of heart attack, stroke and aortic valve disease, why the first big Lp(a)-lowering drug trial (Lp(a)HORIZON) did not reduce events despite a 78% drop in Lp(a), and what the group's posts suggest doing in the meantime.

18 min read59 group posts cited30 studies discussed5 chartsEvidence through Nov 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • Lp(a) is an LDL-like particle with an extra apo(a) tail; 80-90% of the level is genetic, it is fixed from early childhood, and about 1 in 5 people have a high level.
  • Guidelines flag Lp(a) of 125 nmol/L or 50 mg/dL and above; the 2026 ACC/AHA guideline says to measure it at least once in adulthood, and a level of 250 nmol/L carries at least a two-fold long-term risk.
  • In Lp(a)HORIZON (8,322 patients), pelacarsen cut Lp(a) by about 78% over a median 4.7 years, yet the primary endpoint occurred in 12.3% versus 12.1% on placebo (hazard ratio 1.02).
  • Statins, which the group's admins consider proven even in high Lp(a), raise Lp(a) only about 5-20%; a UK Biobank genetic analysis estimated that roughly 19 mg/dL lower lifelong LDL-C offsets the extra risk of an Lp(a) of about 123 nmol/L.
  • Observational MESA data suggest the risk from high Lp(a) concentrates in people with CAC of 100 or more, hsCRP of 2 mg/L or more, or a large waist-to-hip ratio, though these are associations, not proof.
In this summary
  1. What Lp(a) is
  2. What the evidence says about risk
  3. Lowering Lp(a): drugs and trials
  4. Existing treatments and supplements
  5. Nuances and common misconceptions
  6. What this means for you
  7. Frequently asked questions
  8. The evidence behind this summary

Lipoprotein(a), written Lp(a) and pronounced "L-P-little-a", is a cholesterol-carrying particle that looks like LDL but has an extra protein tail attached. Its level is set almost entirely by your genes, it barely changes over a lifetime, and a high level is common: roughly 1 in 5 people. It has been linked to heart attack, stroke, aortic valve stenosis and peripheral artery disease, and it can be high even when a standard cholesterol panel looks normal.12

Because the level is inherited and stable, the group's posts and the 2026 ACC/AHA lipid guideline converge on one simple message: get it measured at least once.23 Testing does not change your number, but it tells you how seriously to manage the risk factors you can influence.2

What to do about a high result is now genuinely uncertain. In September 2026 the first large outcome trial of an Lp(a)-lowering drug, Lp(a)HORIZON, was announced as a failure, and the full results in November confirmed there was no reduction in heart attacks or strokes despite a very large drop in Lp(a).45

1 in 5people have a high Lp(a) level1
80–90%of your level is set by your genes, and it is fixed from early childhood1
125 nmol/L(50 mg/dL) and above is "high" in the 2026 ACC/AHA guideline3
78%drop in Lp(a) in Lp(a)HORIZON, with no fewer heart attacks or strokes5

What Lp(a) is

An LDL particle is a globule of fat wrapped in a protein called apolipoprotein B (apoB). Lp(a) is built on the same plan, with one major difference: it carries an additional tail made of apolipoprotein(a), or apo(a), attached to the apoB-100 part of the particle.17 The tail loops into segments called kringles, and people carry anywhere from 1 to more than 40 copies of one kringle type. The fewer the copies, the smaller the particle and the higher the Lp(a) level, apparently because liver cells find it easier to produce and secrete the smaller particles.7

Lp(a) is counted inside your LDL-C

Louis Nervegna uses a boats-and-cargo analogy. LDL and Lp(a) are different "boats", but both carry the same "cargo", LDL cholesterol. The LDL-C on a lab report therefore reflects cholesterol from both LDL particles and Lp(a) particles, and in people with very high Lp(a) a significant share of reported LDL-C may come from Lp(a).89 He extends the analogy to apoB: apoB is the "sign" on every atherogenic boat (LDL, VLDL and Lp(a)), so an apoB test counts the total number of such particles.10 Lp(a) and VLDL (which carries most triglyceride) are both apoB-tagged too.11

Genetics and stability

Gokhan Can's explainer summarizes the key facts: Lp(a) level is 80-90% genetically determined, is fully expressed by 1-2 years of age, reaches adult levels by about age 5, and outside of acute inflammatory states stays relatively stable regardless of lifestyle. Elevated Lp(a) is estimated to affect more than 1.4 billion people worldwide, making it the most common genetic lipid disorder.1

Why it may be more dangerous than LDL

A Nature feature quoted in the group says that, particle for particle, Lp(a) carries about six times the risk of LDL. Possible reasons include more effective cholesterol deposition in artery walls, more inflammation, and, in Børge Nordestgaard's view, an effect on blood clotting.7

Several mechanisms are discussed in the posts:

  • Cholesterol deposition. The apo(a) protein makes the particle particularly sticky inside the artery wall, so LDL cholesterol gets trapped and forms plaque.812
  • Clotting. Apo(a) closely resembles plasminogen, the body's clot-dissolving protein, and competes with it.1314 Louis also describes apo(a) as prothrombotic, making clots form more easily if a plaque ruptures.8
  • Oxidized phospholipids (OxPL). Lp(a) is the main carrier of these damaged, inflammatory fats in the blood, via a lysine binding site in the kringle IV type 10 domain. A commentary summarized in the group says OxPL switch on monocytes to make more tissue factor, a main trigger of clotting, and that patients with stents who had higher Lp(a) and OxPL had stronger clots on a specialized test.1314 Some authors suggest that Lp(a) harm comes largely through OxPL, and that OxPL content may predict risk better than Lp(a) itself, which could explain why some people with very high Lp(a) have clean arteries.15

High Lp(a) is linked to coronary heart disease, heart attack, ischemic stroke, aortic valve stenosis and peripheral artery disease.116

How much more often each outcome occurs at the highest versus lowest Lp(a) levels in large population studies (from 1.2-fold for all-cause death to 5-fold for coronary narrowing), and whether genetic (Mendelian randomization) studies back it up. From Gokhan Can's Lp(a) explainer.
How much more often each outcome occurs at the highest versus lowest Lp(a) levels in large population studies (from 1.2-fold for all-cause death to 5-fold for coronary narrowing), and whether genetic (Mendelian randomization) studies back it up. From Gokhan Can's Lp(a) explainer.1

Louis notes that people with very low or undetectable Lp(a) have no significant ill effects, so it does not appear essential in modern humans; it may have offered ancestors some advantage, and high Lp(a) might be linked to lower risk of diabetes and hemorrhagic stroke, though it strongly raises cardiovascular risk.17

What the evidence says about risk

Thresholds and how much risk

Gokhan's explainer cites levels above 50 mg/dL or 125 nmol/L as associated with increased atherosclerotic cardiovascular disease (ASCVD) risk, along with other cited findings such as an odds ratio of 1.48 for heart attack above 50 mg/dL in INTERHEART and roughly doubled ischemic stroke risk with smaller apo(a) isoforms and higher levels.1 The 2026 ACC/AHA guideline, as summarized by Louis, defines high Lp(a) as 125 nmol/L (50 mg/dL) or more, associated with about a 1.4-fold increased long-term risk of heart attack or stroke, and says 250 nmol/L is associated with at least a two-fold risk.3

Louis cites a review stating that in primary prevention every 50 mg/dL increase in Lp(a) corresponds to a hazard ratio of 1.16 for cardiovascular mortality. His own linear extrapolation (250 mg/dL implying roughly an 80% higher risk) is an illustration, not a trial result.18

A Mass General Brigham registry analysis suggested the usual cutoff may be too high. The 125 nmol/L guideline threshold is the 80th percentile, yet major adverse cardiovascular event risk over more than a decade was already 14% higher in the 51st-70th percentile (42-111 nmol/L; adjusted HR 1.14, 95% CI 1.05-1.24), and the hazard ratio rose to 1.21 for the 71st-90th percentile (112-215 nmol/L).19

Risk starts rising well below the guideline cutoffMajor adverse cardiovascular events over more than a decade by Lp(a) percentile, Mass General Brigham registry, versus the lowest half
interval clear of 195% confidence interval
51st–70th percentile (42–111 nmol/L)1.14 (1.05–1.24)
71st–90th percentile (112–215 nmol/L)1.21
Source: 19
Show data
Adjusted hazard ratio95% CI
51st–70th percentile (42–111 nmol/L)1.141.05–1.24
71st–90th percentile (112–215 nmol/L)1.21–

In the Women's Health Study, followed for 30 years with 3,662 first major cardiovascular events, the top versus bottom quintile hazard ratios were 1.70 for hsCRP, 1.36 for LDL cholesterol and 1.33 for Lp(a). Each contributed independently, and the combination predicted best.20

Lp(a), LDL and inflammation each add riskWomen's Health Study, 30 years, 3,662 first major cardiovascular events: top versus bottom fifth of each marker
hsCRP (inflammation)1.70
LDL cholesterol1.36
Lp(a)1.33
Source: 20
Show data
Hazard ratio95% CI
hsCRP (inflammation)1.70–
LDL cholesterol1.36–
Lp(a)1.33–

Lp(a) and LDL lowering: a genetic estimate

A UK Biobank natural-randomization (genetic) analysis by Brian Ference, covering 445,765 participants, compared average Lp(a) (20 nmol/L) with higher Lp(a) (123 nmol/L). Lifelong higher Lp(a) was associated with a projected 37% higher risk of major coronary events, and that excess was completely offset in people who also had genetically lower LDL-C.21 The offset required LDL-C about 0.5 mmol/L (19 mg/dL) lower at every age, and the later LDL lowering starts, the larger the reduction needed. For Lp(a) 150 nmol/L above the median, the needed reduction was 0.6, 0.7, 0.9 and 1.1 mmol/L if started at ages 30, 40, 50 and 60; for 250 nmol/L above the median, starting at 50 or 60 needed 1.5 or 1.9 mmol/L.21 This is a modeled genetic estimate, not a treatment trial.

The later LDL lowering starts, the more of it is neededLifelong LDL-C reduction estimated to offset Lp(a) 150 nmol/L above the median, by age at which lowering starts (UK Biobank genetic analysis)
Start at 300.6 mmol/L
Start at 400.7 mmol/L
Start at 500.9 mmol/L
Start at 601.1 mmol/L
0.6 mmol/L ≈ 23 mg/dL; 1.1 mmol/L ≈ 43 mg/dL. A modeled genetic estimate, not a treatment trial. Source: 21
Show data
LDL-C reduction (mmol/L)
Start at 300.6 mmol/L
Start at 400.7 mmol/L
Start at 500.9 mmol/L
Start at 601.1 mmol/L

Risk modifiers in MESA

Louis has shared several analyses from the MESA cohort, a prospective observational study that can show associations but not causality.2223

  • Coronary calcium (CAC). Risk was highest with elevated Lp(a) and CAC of 100 or more; with CAC of 1-99 the risk was about the same whether Lp(a) was high or low, and over a decade a CAC of zero seemed to "trump" high Lp(a), per a quoted investigator.2425 A later JACC analysis found higher relative risk with elevated Lp(a) across CAC strata, but low absolute event rates when CAC was 0.26 A counterpoint quoted from a National Lipid Association update: Lp(a) is not consistently associated with baseline CAC or CAC progression, so a zero score does not remove Lp(a)-related risk, particularly in younger adults.27
  • Inflammation (hsCRP). Over 13.6 years and 684 events, no significant risk from Lp(a) was seen when hsCRP was under 2 mg/L. With hsCRP of 2 or more, Lp(a) of 50-99.9 mg/dL had HR 1.36 and 100 mg/dL or more had HR 2.09 (interaction p = 0.04). Participants were lower-risk people averaging 62 years, so applicability to younger or higher-risk people is unclear.28
  • Visceral fat. Lp(a) of 50 mg/dL or more combined with a waist-to-hip ratio at or above the 90th percentile carried an HR of 2.34 (95% CI 1.61-3.40); in the lower two waist-to-hip tertiles Lp(a) was not significantly associated with ASCVD, and BMI did not modify the risk. Louis suggests losing visceral fat and liver fat is important with high Lp(a), while noting the study is observational.23

Louis summarizes these as three markers that seem to offer extra protection in people with high Lp(a): CAC below 100, hsCRP below 2 mg/L and low visceral fat, adding "please don't bet your life on this being true."2225

Lowering Lp(a): drugs and trials

The Lp(a)HORIZON trial

Pelacarsen, developed by Ionis and tested by Novartis, was the first drug to be tested in a large randomized outcome trial for Lp(a) lowering.429 Details from the posts:

  • Design. 8,322 patients (797 sites, 42 countries, ages 18-80) with a prior heart attack, ischemic stroke or symptomatic peripheral artery disease and Lp(a) of at least 70 mg/dL, randomized to pelacarsen 80 mg monthly by self-injection or placebo; median follow-up 57 months (4.7 years). All were on maximally tolerated lipid-lowering therapy.530
  • Lp(a) effect. Lp(a) fell about 78%; at 12 months it was 64.4 versus 233.4 nmol/L on placebo (baseline median 236).530
  • Outcome. The primary endpoint (cardiovascular death, heart attack, stroke or urgent procedure) occurred in 511 patients (12.3%) on pelacarsen and 503 (12.1%) on placebo (hazard ratio 1.02, 95% CI 0.90-1.15, P = 0.76).5 In patients with baseline Lp(a) of 90 mg/dL or more, the rates were 12.3% in both groups (hazard ratio 1.00).5
  • Safety. Serious adverse events occurred in 37.3% on pelacarsen versus 41.1% on placebo, though flu-like symptoms, injection-site reactions and events leading to discontinuation were more common on pelacarsen.530

Louis stresses there was "not even a trend" towards benefit.5

Lp(a)HORIZON: Lp(a) fell 78%, events did notShare of patients with each outcome over a median 4.7 years (8,322 patients with established cardiovascular disease)
PelacarsenPlacebo
Primary endpoint (CV death, heart attack, stroke or urgent procedure)12.3%12.1%
Primary endpoint, baseline Lp(a) 90 mg/dL or more12.3%12.3%
Serious adverse events37.3%41.1%
Primary endpoint hazard ratio 1.02 (95% CI 0.90–1.15), P = 0.76. Source: 530
Show data
PelacarsenPlacebo
Primary endpoint (CV death, heart attack, stroke or urgent procedure)12.3%12.1%
Primary endpoint, baseline Lp(a) 90 mg/dL or more12.3%12.3%
Serious adverse events37.3%41.1%

The full slides and a Nissen interview were also shared.3132 Steven Nissen, the senior author, said a single neutral trial does not prove a lack of benefit from lowering Lp(a), and pointed to ongoing trials in other populations such as primary prevention or aortic stenosis.30

Louis said the result "is going to seriously call into question the assumption that Lp(a) is directly causal in heart disease."4 A New York Times article quoted in the group raised the possibility that Lp(a) may be a marker of risk, "like white hair is a mark of aging", though many researchers were not ready to abandon the hypothesis.33 Louis himself still leans toward causality because of Mendelian randomization studies, while acknowledging that tool has a short track record.34

Why might it have failed?

Several explanations have been aired, and none is proven:

  • Patients were already very well treated. Participants were on optimal treatment, with some of the lowest LDL-C levels ever seen in a randomized trial; a cardiologist quoted by Nature said aggressive LDL lowering may "negate a lot of risk associated with Lp(a)".7 Louis offers a similar speculation: once LDL-C is low enough, there may be too little cholesterol available to cause major damage, even if many Lp(a) particles carry it. He labels this his own speculation.35
  • Statins may neutralize OxPL. 78% of HORIZON patients were on high-intensity statins. Louis proposes that atorvastatin may "disarm" Lp(a) by blocking oxidation; this rests on a lab-based abstract (Sherratt et al., European Heart Journal) in which atorvastatin's active metabolite inhibited the oxidation of Lp(a) and small dense LDL better than other statins, and it remains a hypothesis.36
  • Too short or too late. Atherosclerosis develops over decades while treatment lasted a few years; a cardiologist cited in Nature said four or five years may not be enough, and damage may have been done already.7
  • The population studied. Sam Tsimikas, an Ionis executive and Lp(a) expert, notes that most evidence linking Lp(a) to disease came from general populations, often before aggressive LDL lowering, and the trial enrolled people who already had disease.29 Another summary agrees that neither trial proves Lp(a) or inflammation is non-causal.37

The group placed HORIZON alongside ZEUS, an IL-6 trial where CRP fell 64% yet events were 17.6% versus 17.7%, and older failures such as torcetrapib (HDL up 72%, deaths up from 59 to 93). The lesson drawn: moving a lab number does not guarantee benefit.373839

Tsimikas himself reads HORIZON as a "major success" because it suggests Lp(a) risk may be managed by keeping LDL-C at 65 or lower, blood pressure at 120 or lower, controlling other risk factors and taking proven medicines regularly. In his Lp(a) clinic, about 75% take a statin, 50% ezetimibe and 50% a PCSK9 inhibitor, plus aspirin used judiciously in primary prevention and universally in secondary prevention.6 Weigh this against his affiliation with the drug's developer.29

Other Lp(a)-lowering drugs

Other agents produce very large drops in Lp(a), but outcome data are pending. Lepodisiran, an siRNA, lowered Lp(a) by 93.9% (placebo-adjusted) at 400 mg in a 320-person NEJM trial, lasting up to a year with only mild injection-site reactions.40 A single-dose therapy lowered it by more than 94% for nearly a year in a phase 1 trial,41 and a Lilly drug cut it 94% in a mid-stage trial; Gokhan noted the key question is whether these drugs reduce cardiovascular events.42

How much different treatments move Lp(a)Change in Lp(a) reported in the group's posts. Only pelacarsen has outcome data so far, and it showed no reduction in events.
Lepodisiran (siRNA, single trial)−94%
Pelacarsen (Lp(a)HORIZON)−78%
Niacin (small trial in men)−28%
PCSK9 inhibitors−27%
Statins+5 to +20%
Figures come from different trials and populations, so they are not a head-to-head comparison. Source: 540434445
Show data
Value
Lepodisiran (siRNA, single trial)−94%
Pelacarsen (Lp(a)HORIZON)−78%
Niacin (small trial in men)−28%
PCSK9 inhibitors−27%
Statins+5 to +20%

Existing treatments and supplements

Statins

Statins raise Lp(a) by roughly 5-20% in meta-analyses of randomized trials, but Stanford's Joshua Knowles explains this is clinically unimportant and that statins are an important part of treating genetically high Lp(a).4546 Louis points to more than 25 statin trials, in which lowering LDL by about 75 mg/dL cut heart attack or stroke by about 40% on average, including in people with high Lp(a).1245 A graphic in the group notes that across 147 trials, statins, ezetimibe, fibrates and fish oil did not lower Lp(a).2

PCSK9 inhibitors

A meta-analysis cited by Louis found PCSK9 inhibitors lower Lp(a) by an average of 27%.44 Louis argues that no randomized trial shows PCSK9 inhibitor monotherapy lowers heart attacks, so people taking one mainly to lower Lp(a) should revisit that choice given HORIZON; statins, or statins plus a PCSK9 inhibitor, have outcome evidence in people with high Lp(a).47

Niacin

Louis's views on niacin have changed. He noted that niacin can be very effective at lowering Lp(a) (one member saw a 40% drop on 1,500 mg), a small trial showed about 28% in men, and rare cases of up to 80% are reported, but it has never been proven to reduce heart attacks, strokes or mortality.434849 Two large trials found no added benefit and more side effects when niacin was added to high-dose statins, and he would not combine them.4850 After HORIZON he no longer sees a use case for niacin in high Lp(a), except perhaps for people who refuse all pharmaceuticals.50

Aspirin

Louis suggests baby aspirin may be worth considering in high Lp(a), linking a 2025 review arguing Lp(a) may redefine aspirin's role in primary prevention.51 He also notes aspirin reduces clotting risk.13

Diet and supplements

The evidence here is thin. Ginger 1,600 mg/day for 8 weeks lowered Lp(a) by about 5 ng/mL from a low baseline of 27 in a small trial of 57 men with atherosclerosis.52 Vitamin C at 1 g/day for 8 months did not lower Lp(a) in a randomized trial of 101 healthy adults.53 A PREDIMED-Plus analysis of 348 participants linked a higher share of extra virgin olive oil to about 22% lower Lp(a), but this was observational and significant only in one group.54

Nuances and common misconceptions

  • "My Lp(a) changed a lot, so my intervention worked." Lp(a) is an acute-phase reactant. Infection, surgery, extreme exercise, strong vaccine reactions or inflammatory flares can temporarily shift results, and guidelines advise against testing during acute inflammation. Large swings usually reflect inflammation rather than a supplement or drug.55 Louis also cautioned that a very large reported drop from lifestyle change might simply be a lab error.56
  • "Statins raised my Lp(a), so statins are bad for me." Statins raise Lp(a) only about 5-20% in most cases; a huge increase often points to an unrelated inflammatory issue rather than the statin.4555
  • "Adding Lp(a) improves risk calculators." Adding Lp(a) did not meaningfully improve the accuracy of the PREVENT equations, though an editorial notes measuring it can still personalize risk because Lp(a) is causal.5758
  • "HORIZON proves Lp(a) is harmless." Not so. The trial tested one drug in people with established disease; experts cited in the group say a single neutral trial does not close the question, and the genetic and observational evidence is unchanged.2930

What this means for you

Posts from the group's admins describe the following ideas. None is individual medical advice, and decisions belong with your doctor.

  • Consider asking your doctor to measure Lp(a) once; the 2026 ACC/AHA guideline recommends measuring it at least once in adulthood, and repeat testing is generally not needed because lifestyle changes minimally affect it.3
  • Avoid testing during an acute illness or inflammatory flare, and interpret large swings cautiously.55
  • If high, the posts emphasize driving LDL-C (and apoB) low with proven therapy, since Lp(a) cargo counts toward LDL-C. Statins have outcome evidence in high Lp(a), and Tsimikas's approach adds ezetimibe and PCSK9 inhibitors as needed.612
  • Keep blood pressure and other risk factors controlled; Tsimikas gives targets of LDL-C 65 or lower and blood pressure 120 or lower.6
  • A CAC scan may help refine risk: MESA data suggest CAC of 0 means low 10-year absolute risk, but a zero score does not fully remove risk in younger people.2627
  • Check hsCRP and waist-to-hip ratio, since MESA suggests risk concentrates when these are high.2328
  • Discuss aspirin with your doctor if Lp(a) is high.51
  • Be cautious about unproven Lp(a)-lowering supplements, and avoid combining niacin with high-dose statins.50
  • Watch for outcome trials of newer Lp(a)-lowering drugs.3042

Frequently asked questions

Can I lower my Lp(a) with diet or exercise?

Mostly not. Lp(a) is 80-90% genetic and stable regardless of lifestyle, and lifestyle changes minimally affect it.13 Small studies of ginger or olive oil exist, but none shows a benefit on heart attacks.5254

Is Lp(a) really a cause of heart disease, given the HORIZON result?

The question is open. Louis said HORIZON seriously challenges the assumption, but he remains cautiously optimistic because of Mendelian randomization.434 Others note the patients were already very well treated and treatment may have been too short.7

Does a CAC score of zero mean I can ignore high Lp(a)?

Not entirely. MESA suggests 10-year absolute risk is low with CAC of 0, but a National Lipid Association update quoted in the group says Lp(a) is not consistently tied to CAC, so risk may persist, particularly in younger adults.242627

Do statins make Lp(a) worse?

Slightly (about 5-20%), but the posts argue this does not matter clinically, because statins still reduce heart attacks and strokes in high Lp(a).4546

Why did my Lp(a) jump between tests?

Acute-phase inflammation is a common reason: infection, surgery, extreme exercise or a flare can raise it for weeks.55 Autoimmune and inflammatory conditions are also associated with higher Lp(a).59

The evidence behind this summary30 studies · 3 meta-analyses · 9 trials · 1 MR · 6 observational

The 59 group posts cited above discuss 30 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 3Randomized trials 9Mendelian randomization 1Observational studies 6Reviews & guidelines 7Animal & lab studies 1Other sources 3

Strongest evidence discussed

All 30 studies and sources
Sources from the group (59)
  1. Lipoprotein(a) explained: 80-90% genetic, stable for life, a risk factor beyond LDL Gokhan Can · Oct 05, 2024 · Facebook
  2. Lp(a) explained: an LDL particle with a tail, genetic, unaffected by standard drugs Louis Nervegna · Sep 03, 2026 · Facebook
  3. 2026 ACC/AHA lipid guideline keeps LDL targets and adds Lp(a), apoB and CAC testing Louis Nervegna · Mar 13, 2026 · Facebook
  4. Novartis Lp(a)HORIZON: pelacarsen failed to reduce heart attacks and strokes Louis Nervegna · Sep 04, 2026 · Facebook
  5. Lp(a)HORIZON NEJM: pelacarsen cut Lp(a) 78% with no trend toward fewer events Louis Nervegna · Nov 07, 2026 · Facebook
  6. Tsimikas: Lp(a) risk can be managed with LDL under 65 and tight risk-factor control Louis Nervegna · Nov 10, 2026 · Facebook
  7. Why lowering Lp(a) failed to cut heart attacks in the HORIZON trial, per Nature Louis Nervegna · Nov 03, 2026 · Facebook
  8. Lp(a) carries LDL cholesterol, so LDL-C on a lab report includes Lp(a) cholesterol Louis Nervegna · Jun 14, 2025 · Facebook
  9. Lp(a) carries LDL cholesterol, so lab LDL-C includes cholesterol from Lp(a) particles Louis Nervegna · Oct 10, 2025 · Facebook
  10. ApoB is the 'sign' on atherogenic particles; LDL and Lp(a) carry LDL cholesterol Louis Nervegna · Jun 15, 2025 · Facebook
  11. Lp(a) and triglycerides are ApoB particles, so accepting them but not LDL is odd Louis Nervegna · Jul 21, 2024 · Facebook
  12. Statins cut heart attack and stroke risk in high Lp(a) despite raising it 5-20% Louis Nervegna · Jun 20, 2026 · Facebook
  13. Lp(a) makes clots form more easily and resist breakdown via OxPL and apo(a) Louis Nervegna · Nov 10, 2026 · Facebook
  14. How Lp(a) captures and carries oxidized phospholipids through its apo(a) tail Louis Nervegna · Nov 10, 2026 · Facebook
  15. Why some people with very high Lp(a) have clean arteries: oxidized phospholipids Louis Nervegna · Dec 04, 2025 · Facebook
  16. AHA share: high Lp(a) raises peripheral artery disease risk Louis Nervegna · Aug 07, 2024 · Facebook
  17. Lp(a) has no known essential role in modern humans and may even have minor upsides Louis Nervegna · Sep 16, 2026 · Facebook
  18. High Lp(a) raises CVD death risk 16% per 50 mg/dL, independent of other risk factors Louis Nervegna · May 11, 2024 · Facebook
  19. Lp(a) risk starts above the median, well below the 125 nmol/L guideline cutoff Louis Nervegna · May 09, 2024 · Facebook
  20. NEJM: hs-CRP, LDL and Lp(a) each predicted 30-year CVD risk in women, best combined Louis Nervegna · Aug 31, 2024 · Facebook
  21. High Lp(a) risk offset by about 19 mg/dL lower lifelong LDL-C in UK Biobank analysis Louis Nervegna · Oct 23, 2025 · Facebook
  22. MESA: CAC under 100, hsCRP under 2 and low visceral fat may protect those with high Lp(a) Louis Nervegna · Nov 10, 2026 · Facebook
  23. MESA: high Lp(a) raised ASCVD risk 2.34-fold only in people with large waist-to-hip ratio Louis Nervegna · Oct 18, 2025 · Facebook
  24. In MESA, high Lp(a) mattered mainly when CAC was 100 or higher Louis Nervegna · Jun 01, 2024 · Facebook
  25. MESA: high Lp(a) mostly matters when CAC is 100 or above Louis Nervegna · Jul 18, 2024 · Facebook
  26. High Lp(a) with a CAC score of zero still means low 10-year event risk (JACC) Louis Nervegna · May 29, 2026 · Facebook
  27. A CAC score of zero does not eliminate risk from high Lp(a), especially in younger adults Louis Nervegna · Apr 01, 2024 · Facebook
  28. MESA: high Lp(a) raised CVD risk only when hsCRP was 2 mg/L or higher Louis Nervegna · Jul 12, 2024 · Facebook
  29. Tsimikas on why Lp(a) HORIZON missed its endpoint despite strong Lp(a)-risk evidence Louis Nervegna · Sep 05, 2026 · Facebook
  30. Cleveland Clinic: pelacarsen did not cut CV events in Lp(a)HORIZON (12.3% vs 12.1%) Louis Nervegna · Nov 07, 2026 · Facebook
  31. Slides from the Lp(a)HORIZON AHA 2026 presentation by Steven Nissen Louis Nervegna · Nov 07, 2026 · Facebook
  32. Steven Nissen discusses Lp(a)HORIZON results in an AHA 2026 late-breaker interview Louis Nervegna · Nov 08, 2026 · Facebook
  33. After the Novartis pelacarsen Lp(a) trial failed, doubts arise about Lp(a) as a cause Louis Nervegna · Sep 14, 2026 · Facebook
  34. Video doubts Lp(a) causality; Louis still favors it based on Mendelian randomization Louis Nervegna · Jan 11, 2026 · Facebook
  35. Very low LDL-C cancels much of the risk from high Lp(a), possibly explaining HORIZON Louis Nervegna · Sep 11, 2026 · Facebook
  36. Atorvastatin may 'disarm' Lp(a) by blocking oxidation, a theory for HORIZON's failure Louis Nervegna · Nov 10, 2026 · Facebook
  37. Pelacarsen (Lp(a)HORIZON) and ziltivekimab (ZEUS) cut their targets but not heart events Louis Nervegna · Nov 13, 2026 · Facebook
  38. Pelacarsen and ziltivekimab lowered their targets but not events, and why that matters Louis Nervegna · Nov 08, 2026 · Facebook
  39. Preview of HORIZON (Lp(a)) and ZEUS (IL-6): improved bloodwork is not enough Louis Nervegna · Nov 06, 2026 · Facebook
  40. Lepodisiran siRNA cut Lp(a) by 93.9% at 400 mg in a 320-person NEJM trial Louis Nervegna · May 07, 2025 · Facebook
  41. Single-dose Lp(a) therapy cut Lp(a) by more than 94% for nearly a year in a phase 1 trial Louis Nervegna · Dec 10, 2024 · Facebook
  42. Lilly's experimental drug cut Lp(a) by 94% in a mid-stage trial; outcome data pending Gokhan Can · Mar 30, 2025 · Facebook
  43. Niacin lowered Lp(a) about 28% in a small trial but failed outcome trials with statins Louis Nervegna · Jan 14, 2026 · Facebook
  44. PCSK9 inhibitors lower Lp(a) by an average of 27%, per meta-analysis Louis Nervegna · Sep 13, 2025 · Facebook
  45. Statins raise Lp(a) 5-20% yet still cut heart attack and stroke, including with high Lp(a) Louis Nervegna · Jan 21, 2025 · Facebook
  46. Statins remain essential for high Lp(a) even though they raise Lp(a) 5-20% Louis Nervegna · Apr 06, 2025 · Facebook
  47. No trial shows PCSK9 inhibitor monotherapy cuts heart attacks; HORIZON undermines Lp(a) Louis Nervegna · Oct 31, 2026 · Facebook
  48. Niacin can cut Lp(a) (one member saw 40% with 1500 mg) but has no outcome proof Louis Nervegna · Jan 19, 2024 · Facebook
  49. Niacin has lowered Lp(a) up to 80% in rare cases but is a long shot Louis Nervegna · Aug 13, 2025 · Facebook
  50. Niacin for CVD prevention: no reason to use it given proven options, says the poster Louis Nervegna · Sep 19, 2026 · Facebook
  51. Baby aspirin may be worth considering for people with high Lp(a) Louis Nervegna · Jul 13, 2025 · Facebook
  52. Ginger 1,600 mg/day for 8 weeks lowered Lp(a), hsCRP and fasting glucose in a small RCT Louis Nervegna · Apr 28, 2026 · Facebook
  53. Vitamin C 1 g/day for 8 months did not lower Lp(a) in a randomized trial Louis Nervegna · Jun 03, 2024 · Facebook
  54. Higher extra virgin olive oil share was linked to lower Lp(a) in PREDIMED-Plus Louis Nervegna · Mar 14, 2026 · Facebook
  55. Big swings in Lp(a) usually reflect acute inflammation, not an intervention working Louis Nervegna · Jun 20, 2026 · Facebook
  56. Anecdote: large Lp(a) drop reported after diet and lifestyle changes, possibly a lab error Louis Nervegna · Mar 14, 2025 · Facebook
  57. Adding Lp(a) does not improve the accuracy of the PREVENT risk calculator Louis Nervegna · Jun 04, 2025 · Facebook
  58. Adding Lp(a) does not improve PREVENT 10-year risk prediction, but personalizes risk Louis Nervegna · Aug 16, 2025 · Facebook
  59. Autoimmune and inflammatory diseases linked to elevated Lp(a) in ~50,000 patients Louis Nervegna · Sep 14, 2026 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary